Peptides for Weight Loss in Women: What the Research Shows

This article discusses off-label uses of FDA-approved GLP-1 receptor agonists (including in PCOS and menopausal populations). Off-label prescribing is permitted under the practice of medicine, but PCOS and menopausal central adiposity are not FDA-approved indications for any GLP-1 receptor agonist. Superpower dispenses GLP-1 receptor agonists only for their FDA-approved indications. This content is editorially independent and does not constitute promotion of off-label use.

Key Takeaways

• Compounds covered: Semaglutide, tirzepatide, liraglutide, tesamorelin
• Goal area: Weight loss and body recomposition in women, with specific attention to menopause, PCOS, and lean-mass preservation
• Evidence range: Phase III RCTs (semaglutide, tirzepatide, liraglutide) with majority-female cohorts; Phase III tesamorelin data in HIV lipodystrophy; PCOS-specific Phase 3 data for liraglutide
• Regulatory range: Includes FDA-approved compounds (for approved indications) and off-label uses; none are FDA-approved specifically for weight loss in women defined by hormonal status
• Key biomarkers for women's weight loss: Fasting insulin, HbA1c, TSH, free T3, hs-CRP, LH, FSH, estradiol (PCOS/menopause context), IGF-1
• As of April 2026: Semaglutide is FDA-approved as Wegovy for chronic weight management; tirzepatide is FDA-approved as Zepbound. Neither has a sex-specific or menopause-specific indication — these are population-level approvals.
• Bottom line: GLP-1 receptor agonists have the strongest evidence for weight loss in women, with Phase III trial cohorts that were 75 to 78% female; lean-mass preservation requires intentional dietary and exercise strategy alongside pharmacotherapy.

Understanding Weight Regulation in Women: The Biology

Weight regulation in women involves the same core energy-balance pathways that apply broadly — hypothalamic appetite signaling, adipose tissue lipolysis and lipogenesis, insulin sensitivity and glucose metabolism — but with additional hormonal modulators that create female-specific patterns across the lifespan.

Estrogen is the primary modulator. It influences fat distribution, directing preferential storage toward subcutaneous rather than visceral depots at lower adiposity, and shifts this distribution toward visceral fat accumulation as estrogen declines during the menopausal transition. A longitudinal SWAN study by Lovejoy and colleagues published in the International Journal of Obesity in 2008 documented that the menopausal transition is associated with increased visceral fat accumulation and decreased energy expenditure, independent of aging alone. This shift in fat depot has metabolic consequences: visceral fat is more metabolically active and more strongly associated with insulin resistance and cardiovascular risk than subcutaneous fat.

Polycystic ovary syndrome introduces a different hormonal dysregulation: elevated androgens, LH hypersecretion, and insulin resistance form a self-reinforcing cycle that both promotes weight gain and is worsened by it. Hypothyroidism — more prevalent in women — independently slows metabolic rate and can account for several kilograms of weight gain even without severe hormone deficiency.

Peptides interact with weight regulation in women through the same pathways they do broadly — GLP-1 receptor agonism, GH/IGF-1 axis modulation — but the hormonal context shapes both the baseline metabolic state and the expected response. Understanding that context is part of what a thorough provider evaluation addresses before any compound is considered.

Peptides Studied for Women's Weight Loss: A Quick Comparison

The following peptides have published evidence relevant to weight loss, including data from female-majority or female-specific populations. They are listed by strength of clinical evidence.

• Compound: Semaglutide
  • Mechanism for women's weight loss: GLP-1 receptor agonism — hypothalamic appetite suppression, gastric slowing, insulin sensitization
  • Evidence: Phase III RCT (STEP 1, 74% female; STEP 5, 77.6% female; STEP TEENS for adolescents)
  • FDA status: FDA-approved as Wegovy for chronic weight management (BMI ≥30 or ≥27 with comorbidity); as Ozempic for type 2 diabetes
  • SP availability: May be available through Superpower's licensed provider network following clinical evaluation for eligibility. Superpower dispenses the FDA-approved branded product (Wegovy/Ozempic) for the approved indication and does not offer compounded semaglutide.
  • Route: Subcutaneous injection
• Compound: Tirzepatide
  • Mechanism for women's weight loss: Dual GIP/GLP-1 receptor agonism — additive appetite and metabolic effects
  • Evidence: Phase III RCT (SURMOUNT-1, majority female; body-composition substudy 73% female)
  • FDA status: FDA-approved as Zepbound for chronic weight management; as Mounjaro for type 2 diabetes
  • SP availability: May be available through Superpower's licensed provider network following clinical evaluation for eligibility. Superpower dispenses the FDA-approved branded product (Zepbound/Mounjaro) for the approved indication and does not offer compounded tirzepatide.
  • Route: Subcutaneous injection
• Compound: Liraglutide
  • Mechanism for women's weight loss: Daily GLP-1 receptor agonism; Phase 3 RCT evidence in PCOS-specific female population
  • Evidence: Phase III RCT (SCALE, N=3,731); Phase 3 PCOS-specific RCT (Elkind-Hirsch et al. 2022)
  • FDA status: FDA-approved as Saxenda for chronic weight management in adults with BMI ≥ 30 or ≥ 27 with a weight-related comorbidity (and in adolescents aged 12 and older with obesity); PCOS use is off-label
  • SP availability: May be available through Superpower's licensed provider network following clinical evaluation for eligibility, dispensed as the FDA-approved branded product (Saxenda) for the approved chronic weight management indication. Superpower does not offer compounded liraglutide.
  • Route: Subcutaneous injection (daily)
• Compound: Tesamorelin
  • Mechanism for women's weight loss: GHRH analog — GH-mediated visceral fat lipolysis; female-specific GH trial data in postmenopausal abdominal obesity
  • Evidence: Phase III RCT (HIV-associated lipodystrophy); Franco et al. 2005 placebo-controlled GH trial in postmenopausal women
  • FDA status: FDA-approved as Egrifta for HIV-associated lipodystrophy only; use for general fat loss or menopausal adiposity is off-label and not FDA-approved
  • SP availability: Not currently available through Superpower; tesamorelin is a biologic and cannot be lawfully compounded under Section 503A
  • Route: Subcutaneous injection

Peptides Studied for Women's Weight Loss: Individual Profiles

Each compound addresses weight regulation through a different mechanism and carries a different evidence base in female populations. A provider will consider hormonal context, comorbidities, and individual metabolic profile — not a general female category — when evaluating any of these compounds.

Semaglutide

Semaglutide is a GLP-1 receptor agonist, available as Ozempic (type 2 diabetes) and Wegovy (weight management). For weight loss, it reduces appetite through hypothalamic GLP-1 receptor signaling, slows gastric emptying, and improves insulin sensitivity — mechanisms that are relevant regardless of sex, but whose effectiveness has been specifically demonstrated in predominantly female trial populations. The landmark STEP 1 trial, published by Wilding and colleagues in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity and achieved mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg weekly, compared with 2.4% with placebo; approximately 74% of the cohort was female. [Phase III RCT] The STEP 5 two-year trial by Garvey and colleagues in Nature Medicine in 2022 confirmed 15.2% sustained weight loss over 104 weeks in a cohort that was 77.6% female. The STEP 1 trial by Wilding and colleagues, published in the New England Journal of Medicine in 2021, reported that semaglutide 2.4 mg produced substantial weight loss with a body-composition shift favoring loss of fat mass relative to lean mass, though absolute lean mass decreased alongside the fat loss. Semaglutide is FDA-approved as Wegovy for chronic weight management. May be available through Superpower's licensed provider network following clinical evaluation for eligibility, dispensed as the FDA-approved branded product for the approved indication. Superpower does not offer compounded semaglutide. For postmenopausal women, a 2024 retrospective cohort study by Hurtado and colleagues in Menopause reported 16% total body-weight loss at 12 months in postmenopausal women using semaglutide with concurrent hormone therapy versus 12% without — an observational finding in off-label combination use that does not constitute an FDA-approved combination indication. Weight regain after discontinuation is documented: a 2022 STEP 1 extension study by Wilding and colleagues found two-thirds of prior weight loss regained within 12 months of stopping semaglutide.

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist, available as Mounjaro (type 2 diabetes) and Zepbound (weight management). Its dual receptor mechanism produces appetite suppression and insulin sensitization through both GLP-1 and GIP pathways. In SURMOUNT-1, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022, tirzepatide 15 mg produced mean weight loss of 20.9% at 72 weeks compared with 3.1% placebo in a majority-female cohort. [Phase III RCT] A 2025 body-composition substudy by Look and colleagues in Diabetes, Obesity and Metabolism found that approximately 75% of weight lost was fat mass and 25% lean mass, consistent across subgroups including women, in the SURMOUNT-1 substudy cohort (73% female). Tirzepatide is FDA-approved as Zepbound for chronic weight management. May be available through Superpower's licensed provider network following clinical evaluation for eligibility, dispensed as the FDA-approved branded product for the approved indication. Superpower does not offer compounded tirzepatide. A systematic review by Bikou and colleagues in Expert Opinion on Pharmacotherapy in 2024 found that GLP-1 agonist-induced lean-mass loss ranges from near-zero to 40% of total weight lost, reinforcing the need for high-protein diet and resistance training as an adjunct to pharmacotherapy.

Liraglutide

Liraglutide is a daily GLP-1 receptor agonist, available as Saxenda (weight management) and as generic liraglutide for type 2 diabetes (following discontinuation of the Victoza brand in the US). It carries the GLP-1 agonist mechanism with a shorter half-life than semaglutide. In the SCALE trial published by Pi-Sunyer and colleagues in the New England Journal of Medicine in 2015, liraglutide 3.0 mg produced mean weight loss of 8.4 kg over 56 weeks in 3,731 adults with obesity. [Phase III RCT] For women with PCOS specifically, in off-label use, a Phase 3 RCT by Elkind-Hirsch and colleagues published in Fertility and Sterility in 2022 found liraglutide 3 mg produced 5.7% weight loss and improved free androgen index in women with obesity and PCOS over 32 weeks. A 2023 observational study by Carmina and Longo in the Journal of Clinical Medicine found semaglutide produced 11.5 kg mean weight loss at 6 months in obese PCOS patients unresponsive to lifestyle intervention. Liraglutide is FDA-approved as Saxenda; PCOS use is off-label and requires individual clinical evaluation. A real-world Swiss cohort study by Santini and colleagues in Obesity in 2023 reported greater weight-loss outcomes among women than men treated with liraglutide 3.0 mg — an observational finding that does not establish a causal sex-based effect without randomized comparison.

Tesamorelin

Tesamorelin is a stabilized GHRH analog (Egrifta) that stimulates pituitary GH release to drive lipolysis in visceral adipose tissue — a mechanism distinct from appetite suppression. Its most relevant human data are from HIV-associated lipodystrophy trials. For women specifically, a 12-month placebo-controlled GH trial by Franco and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2005 showed reduced abdominal visceral fat in postmenopausal women with abdominal obesity. The Phase 3 tesamorelin trial by Falutz and colleagues in 2010 showed approximately 18% visceral fat reduction over 52 weeks without glucose perturbation. [Phase III RCT — HIV-associated lipodystrophy only] Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy only. Use for menopausal central adiposity or general fat loss is off-label and not FDA-approved. Because tesamorelin is classified as a biologic, it cannot be lawfully compounded under Section 503A — only the FDA-approved Egrifta is legally available. Not currently available through Superpower.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry the following regulatory statuses relevant to women's weight loss.

• Semaglutide: FDA-approved as Wegovy for chronic weight management (BMI ≥30 or ≥27 with comorbidity) and as Ozempic for type 2 diabetes. FDA approval is for the chronic weight management indication regardless of sex; there is no menopause-, PCOS-, or sex-stratified approved indication for any GLP-1 receptor agonist. Superpower dispenses the FDA-approved branded product and does not offer compounded semaglutide.
• Tirzepatide: FDA-approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. FDA approval is for the chronic weight management indication regardless of sex. Superpower dispenses the FDA-approved branded product and does not offer compounded tirzepatide.
• Liraglutide: FDA-approved as Saxenda for chronic weight management; also available as generic liraglutide for type 2 diabetes. PCOS use is off-label. FDA approval is for the chronic weight management indication regardless of sex.
• Tesamorelin: FDA-approved as Egrifta for HIV-associated lipodystrophy only. Use for menopausal central adiposity or general fat loss in women is off-label and not FDA-approved. Cannot be compounded; biologic classification under BPCIA.

Considerations When Comparing Peptides for Women's Weight Loss

Selecting a compound for weight loss in women is a clinical decision, not a consumer choice. The female-specific hormonal context adds layers that are not visible in compound rankings or general trial summaries. Direct comparison between these compounds is not straightforward — they have been studied in different populations, at different doses, with different endpoints. Inferring relative effectiveness from separate trials is methodologically unreliable.

Hormonal context and life stage: Perimenopausal and postmenopausal women have a different hormonal baseline than premenopausal women, affecting fat distribution patterns and metabolic rate independently of body weight. Whether hormone therapy is concurrent affects the metabolic environment in which any weight-loss peptide operates.

PCOS and androgen status: Women with PCOS have elevated androgens and insulin resistance as part of the underlying condition — not simply as comorbidities. GLP-1 receptor agonists address the insulin resistance component directly; the androgen effect seen in liraglutide's PCOS trial may be secondary to weight and insulin improvement. A provider familiar with PCOS pathophysiology will evaluate this mechanistic relationship.

Lean-mass risk: GLP-1 receptor agonists produce some lean-mass loss in proportion to total weight loss. For postmenopausal women with already-reduced muscle mass, a review by Prokopidis and colleagues in The Journal of Nutrition, Health and Aging in 2025 highlighted sarcopenic obesity as a particular concern requiring protein and exercise co-intervention. A 2025 review in Current Nutrition Reports by Memel and colleagues found that lean-mass loss of 15 to 40% of total weight lost is reported across GLP-1 studies, and recommends high-protein diet plus resistance training as mitigation.

Thyroid function: Hypothyroidism is more prevalent in women than in men and independently affects metabolic rate and body weight. Thyroid status needs to be assessed before any weight-loss peptide is considered; a GLP-1 agonist operating in an undetected hypothyroid state will produce a blunted response that may be misattributed to the compound.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate individual health history, current medications, and baseline lab results before discussing any compound.

Safety Considerations

Safety considerations for GLP-1 receptor agonists — the most studied class for women's weight loss — include gastrointestinal effects (nausea, vomiting, diarrhea, constipation) that are most pronounced during dose titration and typically attenuate over time. A rodent study by Bjerre Knudsen and colleagues published in Endocrinology in 2010 identified thyroid C-cell tumor development with GLP-1 receptor agonists in rodent models, forming the basis for the FDA Boxed Warning applied to this class. This has not been confirmed in human data at current follow-up durations. For women specifically, the GLP-1 receptor agonist class carries lean-mass loss risk that is of greater clinical significance in postmenopausal women with reduced muscle mass at baseline. Bimagrumab, an investigational antibody that blocks activin type II receptors, has been studied for muscle preservation during GLP-1 weight loss: a study by Nunn and colleagues in Molecular Metabolism in 2024 reported that activin receptor II antibody blockade preserves skeletal muscle mass in preclinical and early-phase contexts. Bimagrumab is not FDA-approved for any indication, is not a peptide, and is not available through Superpower. This reference is provided for mechanistic context only.

Contraindications that apply broadly to GLP-1 weight-loss therapy include:

• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 — contraindicated per FDA labeling for all GLP-1 receptor agonists
• Pregnancy — GLP-1 receptor agonists should be discontinued at least 2 months before a planned pregnancy per FDA labeling; reproductive safety not established
• Active pancreatitis or history of severe pancreatitis — associated in post-marketing reports
• History of hormone-sensitive malignancy — relevant to GH-axis peptides (tesamorelin) given GH's mitogenic signaling context

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides for Women's Weight Loss

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing the expected physiological changes — or whether those changes are beneficial. For women, the relevant baseline panel extends beyond general metabolic markers to include hormonal context.

• Fasting insulin: The most sensitive early marker of insulin resistance. Testing fasting insulin before starting characterizes the metabolic state that GLP-1 receptor agonists most directly address, and is especially relevant in PCOS where insulin resistance is part of the underlying condition.
• HbA1c: A 90-day blood glucose average reflecting longer-term insulin regulation. HbA1c is a key eligibility marker for FDA-approved weight-management indications and a response biomarker during therapy.
• TSH and free T3: Thyroid function assessment is essential for women before any weight-loss intervention. Testing TSH and free T3 excludes thyroid dysfunction as a confounding contributor to weight and metabolic rate.
• Fasting glucose: Captures current glycemic state alongside HbA1c. A fasting glucose reading is included in any comprehensive metabolic baseline.
• Triglycerides: A sensitive cardiovascular metabolic marker. Triglyceride levels respond to GLP-1 therapy and provide both a baseline safety indicator and a response metric.
• hs-CRP: Low-grade inflammation is elevated in visceral adiposity and in PCOS. Testing hs-CRP at baseline documents the inflammatory context before any intervention.
• Estradiol, LH, FSH: For women in perimenopause, postmenopause, or with suspected PCOS, reproductive hormone status informs both the metabolic context and the safety conversation for any hormone-adjacent compound. These are relevant to evaluating whether tesamorelin's GH-axis effects are appropriate in a given hormonal state.
• IGF-1: The primary downstream marker of GH axis activity. Testing IGF-1 establishes a GH-axis baseline relevant to any GHRH-class compound and provides context for interpreting changes in lean-mass during therapy.
• Comprehensive metabolic panel: Liver enzymes (ALT, AST), kidney function markers, and electrolytes provide the safety baseline required for monitoring during any pharmacotherapy course.

The thyroid biomarker panel and the metabolic markers above — fasting insulin, HbA1c, triglycerides, hs-CRP — together form the core baseline for women beginning any weight-loss peptide evaluation. Testing at baseline, 3 months, and 6 months gives the data a timeline that makes responses interpretable. Body composition testing before starting establishes lean-mass baseline, which is particularly important for postmenopausal women at higher sarcopenic risk.

Access and Regulatory Pathways

All peptides discussed in this article require a prescription from a licensed healthcare provider. FDA-approved compounds — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda) — are available through licensed telehealth and in-person providers for their FDA-approved indications. Superpower's licensed provider network dispenses these drugs only as the FDA-approved branded product for the approved chronic weight management indication and does not offer compounded semaglutide, tirzepatide, or liraglutide. Tesamorelin is available only as the FDA-approved biologic Egrifta; under BPCIA it cannot be compounded under Section 503A, and its clinical use is limited to HIV-associated lipodystrophy as the approved indication.

A provider evaluation for any weight-loss compound typically includes a review of health history, current medications, and comorbidities; baseline lab work; and determination of eligibility for specific approved indications. For women, this evaluation also addresses hormonal context: whether menopausal status, PCOS, or thyroid dysfunction is present affects both compound selection and monitoring strategy. Self-directed use without a provider creates risk from dosing uncertainty, contamination from unregulated sources, and the absence of baseline testing that makes any physiological response interpretable.

Understanding Your Baseline

With multiple compounds available — each targeting different mechanisms and carrying different evidence levels in female populations — baseline biomarker data is what transforms the conversation with your provider from a discussion of rankings to an interpretation of what your labs actually show about your metabolic state. For women, this baseline is broader than for a general adult population: it includes hormonal context alongside the standard metabolic markers.

That principle — test first, then decide — is central to Superpower's biomarker testing approach to preventive health. Whether the conversation with your provider leads to an FDA-approved GLP-1 agonist, a concurrent hormone therapy evaluation, or a structured lifestyle-first approach, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

Semaglutide is an FDA-approved prescription medication available as Wegovy (weight management) and Ozempic (type 2 diabetes). Superpower dispenses the FDA-approved branded product and does not offer compounded semaglutide. Contraindications: personal or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2; known hypersensitivity to semaglutide. Warnings: thyroid C-cell tumors observed in rodents (human relevance unknown); pancreatitis; hypoglycemia with insulin or sulfonylureas; acute kidney injury; serious hypersensitivity reactions; diabetic retinopathy complications; suicidal ideation. Not for use in type 1 diabetes. Discontinue at least 2 months before planned pregnancy. Common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue.

Tirzepatide is an FDA-approved prescription medication available as Zepbound (weight management) and Mounjaro (type 2 diabetes). Superpower dispenses the FDA-approved branded product and does not offer compounded tirzepatide. Contraindications and warnings similar in class to semaglutide above. Common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions.

Liraglutide is an FDA-approved prescription medication available as Saxenda (weight management) and as generic liraglutide for type 2 diabetes (following discontinuation of the Victoza brand in the US). PCOS use is off-label and not evaluated or endorsed by the FDA. Contraindications and warnings similar in class to semaglutide above.

Tesamorelin is FDA-approved as Egrifta for the treatment of lipodystrophy in patients with HIV. Uses outside the approved indication, including use for menopausal central adiposity or general fat loss in women, are off-label. Because tesamorelin is classified as a biologic under federal law (BPCIA, 2020), it cannot be lawfully produced through pharmacy compounding under Section 503A. Only Egrifta is legally available in the United States for this compound. Off-label prescribing of the approved product is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA for this use.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses multiple peptide compounds with different regulatory statuses. Some compounds are FDA-approved for specific indications; others are available through compounding. Some uses discussed are off-label. Superpower Health facilitates access to some but not all compounds discussed through licensed healthcare providers. This educational content is editorially independent.